Diabetes Drug To Be Developed By EpiVax With JDRF Program Funding

October 26th, 2007 | Category: Diabetes

EpiVax, Inc, a leader in the field of computational immunology, has announced that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of Type 1 diabetes research, to develop “Epi-13,” a novel therapeutic for

the prevention and treatment of type I diabetes, a devastating and chronic autoimmune disease that affects up to three million Americans today. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Craftsman Collision Donates $10,000 to Juvenile Diabetes Research Foundation
  • EpiVax Receives 600,000 Dollars Grant To Develop Treatment For Diabetes From National Institutes Of Health
  • Special Diabetes Program
  • American Diabetes organization Applauds Congressional Reauthorization Of The Special Diabetes Program
  • New Multi-Million Pound Study To Find The Cause Of Type 1 Diabetes, UK

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.